Table 2.
Tumor response based on mRECIST between the two groups
| Tumor response, n (%) | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| TACE + A group (n = 477) | TACE + AC group (n = 483) | p value | TACE + A group (n = 449) | TACE + AC group (n = 449) | p value | |
| BOR | ||||||
| CR | 79 (16.6) | 111 (23.0) | < 0.001 | 75 (16.7) | 104 (23.2) | < 0.001 |
| PR | 125 (26.2) | 128 (26.5) | 116 (25.8) | 120 (26.7) | ||
| SD | 198 (41.5) | 185 (38.3) | 186 (41.4) | 183 (38.5) | ||
| PD | 71 (14.9) | 52 (10.8) | 68 (15.1) | 56 (10.2) | ||
| NE | 4 (0.8) | 7 (1.4) | 4 (0.9) | 6 (1.3) | ||
| ORR (CR + PR) | 204 (42.8) | 239 (49.5) | 0.003 | 191 (42.5) | 224 (49.9) | 0.002 |
| DCR (CR + PR + SD) | 402 (84.3) | 424 (87.8) | 0.019 | 377 (84.0) | 397 (88.4) | 0.003 |
mRECIST modified Response Evaluation Criteria in Solid Tumors, PSM Propensity score matching, TACE transcatheter arterial chemoembolization, A apatinib, C camrelizumab, BOR best of response, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR objective response rate, DCR disease control rate